Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial

The Lancet Respiratory Medicine 2024 May 10 [Link] Eric Lim, David Waller, Kelvin Lau, Jeremy Steele, Anthony Pope, Clinton Ali, Rocco Bilancia, Manjusha Keni, Sanjay Popat, Mary O’Brien, Nadza Tokaca, Nick Maskell, Louise Stadon, Dean Fennell, Louise Nelson, John Edwards, Sara Tenconi, Laura Socci, Robert C Rintoul, Kelly Wood, Amanda Stone, Dakshinamoorthy Muthukumar, Charlotte Ingle,…

Read More

Leveraging the pleural space for anticancer therapies in pleural mesothelioma

The Lancet Respiratory Medicine 2024 May 10 [Link] Kevin G Blyth, Prasad S Adusumilli, Philippe Astoul, Liz Darlison, Y C Gary Lee, Aaron S Mansfield, Stefan J Marciniak, Nick Maskell, Vasiliki Panou, Tobias Peikert, Najib M Rahman, Marjorie G Zauderer, Daniel Sterman, Dean A Fennell Abstract Most patients with pleural mesothelioma (PM) present with symptomatic…

Read More

Differential expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas

Translational Lung Cancer Research 2024 April 29 [Link] Nancy Alnassar, Jonathan M J Derry, Giuseppe Luigi Banna, Dariusz C Gorecki Abstract Background: The identification of prognostic biomarkers is crucial for guiding treatment strategies in mesothelioma patients. The Duchenne muscular dystrophy (DMD) gene and its specific transcripts have been associated with patient survival in various tumours.…

Read More

Diagnostic Accuracy of Ultrasound Guided Percutaneous Pleural Needle Biopsy for Malignant Pleural Mesothelioma

Journal of Clinical Medicine 2024 April 29 [Link] Carlo Iadevaia, Vito D’Agnano, Raffaella Pagliaro, Felice Nappi, Raffaella Lucci, Simona Massa, Andrea Bianco, Fabio Perrotta Abstract Background/Objectives: Ultrasound (US) has been progressively spreading as the most useful technique for guiding biopsies and fine-needle aspirations that are performed percutaneously. Malignant pleural mesothelioma (MPM) represents the most common…

Read More

BAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma

JTO Clinical and Research Reports 2024 March 29 [Link] Duo Xu, Yanyun Gao, Haitang Yang, Marc Spils, Thomas M Marti, Tereza Losmanová, Min Su, Wenxiang Wang, Qinghua Zhou, Patrick Dorn, Yongqian Shu, Ren-Wang Peng Abstract Introduction: Malignant pleural mesothelioma (MPM) is a rare and universally lethal malignancy with limited treatment options. Immunotherapy with immune checkpoint…

Read More

Pleural mesothelioma from fluoro-edenite exposure: PACAP and PAC1 receptor. A preliminary report

European Journal of Histochemistry 2024 May 2 [Link] Claudia Lombardo, Grazia Maugeri, Agata Grazia D’Amico, Giuseppe Broggi, Rosario Caltabiano, Veronica Filetti, Serena Matera, Velia D’Agata, Carla Loreto Abstract Pleural mesothelioma is a devastating malignancy primarily associated with asbestos exposure. However, emerging evidence suggests that exposure to fluoro-edenite fibers, a naturally occurring mineral fiber, can also…

Read More

Multimodal Treatment of Pleural Mesothelioma with Cytoreductive Surgery and Hyperthermic Intrathoracic Chemotherapy: Impact of Additive Chemotherapy

Cancers 2024 April 20 [Link] Laura V Klotz, Julia Zimmermann, Karolina Müller, Julia Kovács, Mohamed Hassan, Michael Koller, Severin Schmid, Gunnar Huppertz, Till Markowiak, Bernward Passlick, Hans-Stefan Hofmann, Hauke Winter, Rudolf A Hatz, Martin E Eichhorn, Michael Ried Abstract Cytoreductive surgery (CRS) combined with hyperthermic intrathoracic chemoperfusion (HITOC) is a promising treatment strategy for pleural…

Read More

Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights

Open Respiratory Archives 2024 April 5 [Link] Rafael López-Castro, Álvaro Fuentes-Martín, Andrea Medina Del Valle, Tania García Peña, José Soro García, Leticia López González, Ángel Cilleruelo Ramos Abstract MPM stands as a rare malignancy necessitating improved therapeutic strategies due to its limited treatment choices and unfavorable prognosis. The advent of immune checkpoint inhibitors has heralded…

Read More

Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights

Open Respiratory Archives 2024 April 5 [Link] Rafael López-Castro, Álvaro Fuentes-Martín, Andrea Medina Del Valle, Tania García Peña, José Soro García, Leticia López González, Ángel Cilleruelo Ramos Abstract MPM stands as a rare malignancy necessitating improved therapeutic strategies due to its limited treatment choices and unfavorable prognosis. The advent of immune checkpoint inhibitors has heralded…

Read More